Scilex Holding (NASDAQ:SCLX – Get Free Report) insider Jaisim Shah acquired 30,000 shares of Scilex stock in a transaction on Wednesday, October 16th. The stock was purchased at an average price of $0.99 per share, with a total value of $29,700.00. Following the transaction, the insider now directly owns 77,333 shares in the company, valued at approximately $76,559.67. This trade represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Scilex Stock Performance
Scilex stock traded up $0.08 during midday trading on Thursday, reaching $0.95. The stock had a trading volume of 1,165,308 shares, compared to its average volume of 1,058,459. The firm’s fifty day simple moving average is $1.04 and its 200-day simple moving average is $1.26. The stock has a market capitalization of $183.14 million, a P/E ratio of -0.66 and a beta of 1.15. Scilex Holding has a 1-year low of $0.73 and a 1-year high of $2.63.
Scilex (NASDAQ:SCLX – Get Free Report) last issued its earnings results on Tuesday, August 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02. The firm had revenue of $16.37 million during the quarter, compared to the consensus estimate of $13.17 million. On average, sell-side analysts anticipate that Scilex Holding will post -1.19 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
Separately, Alliance Global Partners started coverage on Scilex in a research note on Wednesday. They issued a “buy” rating and a $14.00 target price for the company.
View Our Latest Research Report on Scilex
Scilex Company Profile
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.
Read More
- Five stocks we like better than Scilex
- Bank Stocks – Best Bank Stocks to Invest In
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- What is the Nikkei 225 index?
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- High Flyers: 3 Natural Gas Stocks for March 2022
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Scilex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scilex and related companies with MarketBeat.com's FREE daily email newsletter.